제품 수집
제품 세부정보
Synonyms
CD74, DHLAG, HLADG, II, Ia-GAMMA, p33, CLIP, INVG34
Source
Human CD74, His Tag (CD4-H524c) is expressed from human 293 cells (HEK293). It contains AA Gln 73 - Met 232 (Accession # P04233-2).
Predicted N-terminus: His
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 19.3 kDa. The protein migrates as 28-35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
SDS-PAGE
Human CD74, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-HPLC
The purity of Human CD74, His Tag (Cat. No. CD4-H524c) was greater than 90% as determined by SEC-HPLC.
Bioactivity-SPR
Anti-CD74 Antibody immobilized on CM5 Chip can bind Human CD74, His Tag (Cat. No. CD4-H524c) with an affinity constant of 0.867 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
사용자 리뷰 댓글 남기기
배경 소개
프론티어 진행
의약품 개발 진행- 영어 이름：
HLA-DR antigens-associated invariant chain
- 카테고리：
- 상장 의약품 수：
0 상세
- 임상 의약품 수：
5 상세
- 최고 개발 단계：
Phase 1 Clinical
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
